Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: A double-blind study

American Journal of Psychiatry

Volumn 155, Issue 10, 1998, Pages 1339-1345

  Smith, Ward T ^a   Londborg, Peter D ^b   Glaudin, Vincent ^b   Painter, John R ^b  

^a Summit Research Network   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; XEROSTOMIA;

EID: 0031684469     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.10.1339     Document Type: Article

References (35)

1. Joffe RT, Levitt AJ, Sokolov ST: Augmentation strategies: focus on anxiolytics. J Clin Psychiatry 1996; 57(suppl 7):25-31; discussion 57(suppl 7):32-33
2. Joffe RT, Levitt AJ, Sokolov ST: Augmentation strategies: focus on anxiolytics. J Clin Psychiatry 1996; 57(suppl 7):25-31; discussion 57(suppl 7):32-33
3. Feighner JP, Brauzer B, Gelenberg AJ, Gomez E, Kiev A, Kurland ML, Weiss BL: A placebo-controlled multicenter trial of Limbitrol versus its components (amitriptyline and chlordiazepoxide) in the symptomatic treatment of depressive illness. Psychopharmacology (Berl) 1979; 61:217-225
4. Fawcett J, Edwards JH, Kravitz HM, Jeffriess H: Alprazolam: an antidepressant? alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients. J Clin Psychopharmacol 1987; 7:295-310
5. Calcedo-Ordonez A, Arosemene X, Otero-Perez FJ, Hernandez-Herror C, Garcia A, Moral L, Baeza F, Fernandez Benitez J, Velasco J, Garrido J: Clomipramine/bentazepam combination in the treatment of major depressive disorder. Hum Psychopharmacol 1992; 7:115-122
6. Nolen WA, Haffmans JP, Bouvy PF, Duivenvooren HJ: Hypnotics as concurrent medication in depression: a placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a tricyclic antidepressant. J Affect Disord 1993; 28:179-188
7. Feighner JP, Aden GC, Fabre LF, Rickels K, Smith WT: Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA 1983; 249:3057-3064
8. Smith WT, Glaudin V: Double-blind efficacy and safety study comparing adinazolam mesylate and placebo in depression. Acta Psychiatr Scand 1986; 74:238-245
9. Petty F, Trivedi MH, Fulton M, Rush AJ: Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 1995; 38:578-591
10. Feighner JR, Boyer WF: Selective Serotonin Re-Uptake Inhibitors. Chichester, England, John Wiley & Sons, 1991
11. Nelson JC: Combined treatment strategies in psychiatry. J Clin Psychiatry 1993; 55(Sept suppl):42-49
12. Pollack MH: Innovative uses of benzodiazepines in psychiatry. Can J Psychiatry 1993; 38(Nov suppl):122-126
13. Arky R: Physicians' Desk Reference. Montvale, NJ, Medical Economics Data Production Co, 1994
14. Stark P, Hardison DC: A review of multicenter controlled studies of fluoxetine, imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985; 46:53-58
15. Pollack MH, Rosenbaum JF, Tesar GE, Herman JB, Sachs GS: Clonazepam in the treatment of panic disorder and agoraphobia. Psychopharmacol Bull 1987; 23:141-144
16. Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sacks GS, Herman JB, Cohen LS, Speir SA: Double-blind, placebo-controlled comparison of clonazepam and alprazolam for the treatment of panic disorder. J Clin Psychiatry 1991; 52:69-76
17. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S; Rosenbaum JF: Long-term outcome after acute treatment of panic disorder with alprazolam or clonazepam. J Clin Psychopharmacol 1993; 13:257-263
18. Beauclair L, Fountain R, Annable L, Holobow N, Chouinard G: Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994; 27:111-118
19. Devane LC, Ware RM, Lydiard BR: Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. Psychopharmacol Bull 1991; 27:463-473
20. Herman JB, Brotman AW, Rosenbaum JF: Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. J Clin Psychiatry 1987; 48(Oct suppl):22-28
21. Pecknold JC: Discontinuation reactions to alprazolam in panic disorder. J Psychiatr Res 1990; 27:155-170
22. Hamilton M: Development of a rating scale tor primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
23. Declaration of Helsinki. Bulletin of the Pan American Health Organization 1990; 24:606-609
24. Rickels K, Smith WT, Glaudin V, Weiss C, Settle GP: Comparison of two dosage regimens of fluoxetine in major depression. J Clin Psychiatry 1985; 46:53-58
25. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
26. Kraemer HC, Thiemann S: How Many Subjects? Newbury Park, Calif, Sage Publications, 1987
27. Winer BJ: Statistical Principles in Experimental Design. New York, McGraw-Hill, 1971
28. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-748
29. Pocock SJ: Clinical Trials: A Practical Approach. Chichester, England, John Wiley & Sons, 1983
30. SYSTAT for Windows: Statistics, Version 5. Evanston, III, SYSTAT 1992
31. Smith WT, Glaudin V, Sheridan AQ: Long-term open-label study of adinazolam in depressed outpatients (abstract). Congress Internationale Psychopharmacologie Proceedings (suppl) 1990; 1:84
32. Van Moffaert M, Bartholome F, Cosyns P, De Nayer, AR: A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol 1995; 10:393-405
33. Shen WW: Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Int J Psychiatry Med 1995; 25:277-290
34. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC: Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997; 33: 454-471
35. Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153:311-320